Business
Block listing Interim Review
Block listing Interim Review.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n 3 April 2023\n \n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n \n (\"Fusion\" or the \"Company\")\n \n \n \n \n \n \n Block admission six monthly return\n \n \n \n \n \n \n \n \n Fusion Antibodies plc (AIM: FAB), a contract research organisation providing discovery, design, and optimisation services for therapeutic antibodies to the global healthcare market, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.\n \n \n \n \n \n \n \n Name of company:\n \n \n \n Fusion Antibodies plc\n \n \n \n \n Name of scheme:\n \n \n \n Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021\n \n \n \n \n \n Period of return:\n \n \n \n From 2 October 2022 to 1 April 2023\n \n \n \n \n \n \n Number and class of securities not issued under the scheme at the beginning of the period:\n \n \n 757,083 ordinary shares of 4 pence each in the Company (\"Ordinary Shares\")\n \n \n \n \n \n Number of securities issued under the scheme during the period:\n \n \n \n Nil\n \n \n \n \n \n \n Number of options under the scheme that have lapsed during the period:\n \n \n \n Options over 5000 Ordinary Shares\n \n \n \n \n Balance under the scheme of securities not yet issued at the end of the period:\n \n \n \n 752,083 Ordinary Shares\n \n \n \n \n Number and class of securities originally admitted and the date of admission:\n \n \n \n 917,083 Ordinary Shares on 27 September 2021\n \n \n \n \n Contact name and telephone number:\n \n \n \n James Fair, CFO via Walbrook PR\n +44 (0)20 7933 8780\n \n \n \n \n \n \n \n \n \n \n \n \n \n Enquiries: \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n \n \n \n www.fusionantibodies.com\n \n \n \n \n \n \n Adrian Kinkaid, Chief Executive Officer\n \n \n James Fair, Chief Financial Officer\n \n \n \n \n \n Via Walbrook PR\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Allenby Capital Limited\n \n \n \n \n \n Tel: +44 (0)20 3328 5656 \n \n \n \n \n \n \n James Reeve/Vivek Bhardwaj (Corporate Finance)\n \n \n Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\...